Regeneron Pharmaceuticals, Inc...

Regeneron Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast

Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts

In 2020, Regeneron/Bayer Healthcare’s Eylea Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Diabetic Macular Edema

Regeneron management to meet with Leerink

In 2020, Regeneron/Bayer Healthcare’s Eylea Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Diabetic Macular Edema

6 Drug Stocks Unworthy of Biotech Bull Market

Baird Reiterates an 'Outperform' on Regeneron Pharma (REGN); Think This Stock Still Has Legs

Piper Jaffray Downgrades Regeneron (REGN) to Neutral

Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis

Regeneron downgraded to Neutral from Overweight at Piper Jaffray

ThinkEquity Starts Regeneron Pharma (REGN) at Buy, Sets $120 Price Target

Regeneron initiated with a Buy at ThinkEquity

Regeneron target raised to $115 from $93 at BMO Capital

BofA/Merrill Lynch Upgrades Regeneron Pharma (REGN) to Buy

7 Stocks at New 52-Week Highs

Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012

5 Booming Biotech And Health Care Stocks to Buy Now

Analyst Is Skeptical Of Rival Company's Warnings About Regeneron

Roth Capital Downgrades Regeneron Pharma (REGN) to Neutral

Regeneron downgraded to Neutral from Buy at Roth Capital

4 Overbought Stocks To Watch

REGN Projects Strong Q4 Eylea Sales - Analyst Blog

REGN Projects Strong Q4 Eylea Sales

Biotech Lessons Learned From JPM 2012

Boosting Regeneron's Fair Value on Stronger Outlook for Eylea

Critical Alerts for Coca-Cola, Apache, Peabody Energy, Regeneron, and Ann Inc. Released by Seven Summits Research

Isis CEO Predicts Success For His Cholesterol Medicine ??? And Substantial Delays For Regeneron, Pfizer And Amgen

Regeneron Pharmaceuticals (REGN) Climbed Sharply On Eylea Sales

BorgWarner, Goodyear, Lululemon, Regeneron, Tiffany: U.S. Equity Movers

Emergent BioSciences And Regeneron Gain Attention Going Into 2012

Pre-market Movers For Jan 10 (AA, LULU, REGN, PHG, LIZ, WBMD, TIF)

Regeneron upgraded to Outperform from Neutral at RW Baird

Regeneron Eylea sales dramatically above expectations, says Leerink

Regeneron says Q4 Eylea net sales $24M-$25M

Cramer's 'Mad Money' Recap: Next Week's Game Plan (Update 1)

Global Health Care Outlook

Regeneron to Lift Veil on Eye Drug Success

Jefferies Upgrades Regeneron Pharma (REGN) to Buy

Genentech, Regeneron Reach Settlement in Patent Fight over Vision Drug

Regeneron Settles Dispute